The Patent Finder

Opko Curna, LLC

Also on record
Records under this name other than the patents Opko Curna, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Opko Curna, LLC

PatentTitleStatus Expires Confidence
US 8,153,606Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,921,329Treatment of Erythropoietin (EPO) Related Diseases by Inhibition of Natural Antisense Transcript to Epo
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,012,139Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,895,527Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,074,210Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,927,511Treatment of Vascular Endothelial Growth Factor (VEGF) Related Diseases by Inhibition of Natural Antisense Transcript to VEGF
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,155,754Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,023,822Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,859,515Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,921,330Treatment of Down Syndrome Gene Related Diseases by Inhibition of Natural Antisense Transcript to a Down Syndrome Gene
Formerly held
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited